MYLeukaemia technology

How it Works

During routine diagnostics, the M.D. collects +5 mL extra peripheral/BM aspirate. Same-day courier brings the sample to our central lab, where we isolate viable leukaemia cells & load them into the MYLeukaemia Therapy Guidance Chipset - our bioengineered human bone-marrow avatar.

We challenge the blood cancer cells with 5 clinically used regimens, quantify Leukaemia cell response vs. healthy counterparts tolerance, and produce a tumour-board-ready heatmap that ranks most effective therapeutic options & flags QC. The result complements cytogenetics, flow, PCR and NGS, turning one-size fits all approach/trial-and-error into evidence-guided therapy selection.

For decisions perfectly tailored to your patient unique blood cancer profile.

1

> 100,000 patient leukaemia cells are isolated and integrated in a sophisticated MYLeukaemia Organ-on-Chip Chipset

Isolate Live Cells from Patients’ Blood

2

3

Patient-personalized Bone Marrow Avatar

Functional Precision Oncology sensitivity Testing

Drug testing for clinically used regimens ID's patients’ funcional AML drivers & rank drug sensitivity by FC

Patient-derived blasts colonize a 3D, vascularised Organ-on-Chip, recreating the patient’s bone marrow Leukemic niche within 24h.

MYLeukaemia Therapy Guidance Chipset is an R&D-stage functional precision oncology service (RUO/IVDR-aware). Not CE-IVD. Not a diagnostic. Clinical use restricted to IRB/ethics-approved pilots.

What Makes Our MYLeukaemia Chipset Unique

Designed for clinician-ready therapy ranking between cycles: measured, not guessed, and timely.

72-hour decision support

Unmatched native marrow-like niche bioengineering for clinically relevant, context-aware drug-response readouts.

Human Bone-Marrow avatars

Functional precision (ex vivo)

Functionally tests patient cancer cells beforehand to complement Standard-of-Care diagnostics (cytogenetics, flow, PCR, NGS) for truly personalized therapy choices.

Minimal-burden sampling

Just +5 mL added to routine peripheral or BM draws; no extra procedure.

Clear heatmap, ranked therapy options, QC flags; available clinical trials; in a simple & concise PDF report

Tumour-board-ready outputs

Pilot-ready & IVDR-aware

TRL4 with MVP on multiple AML cell lines; 20-patient pilot next; CE-IVD horizon ~24-36 months.